Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HARMONY BIOSCIENCES HOLDINGS, INC.

(HRMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Harmony Biosciences to Conduct Phase 3 Trial of Pitolisant for Treatment of Idiopathic Hypersomnia

12/01/2021 | 10:37am EST


ę MT Newswires 2021
All news about HARMONY BIOSCIENCES HOLDINGS, INC.
01/10INSIDER SELL : Harmony Biosciences Holdings
MT
01/07INSIDER SELL : Harmony Biosciences Holdings
MT
01/05Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference
PR
2021HARMONY BIOSCIENCES HOLDINGS, INC.(N : HRMY) added to S&P Pharmaceuticals Select Industry ..
CI
2021HARMONY BIOSCIENCES HOLDINGS, INC.(N : HRMY) added to NASDAQ Biotechnology Index
CI
2021Harmony Biosciences to be Included in Nasdaq Biotechnology Index
MT
2021Harmony Biosciences to be Added to the Nasdaq Biotech Index
PR
2021Harmony Biosciences Publishes Pitolisant Efficacy Data In CNS Drugs
PR
2021Harmony Biosciences Holdings, Inc. Publishes Pitolisant Efficacy Data In CNS Drugs
CI
2021INSIDER SELL : Harmony Biosciences Holdings
MT
More news
Analyst Recommendations on HARMONY BIOSCIENCES HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 306 M - -
Net income 2021 38,5 M - -
Net cash 2021 12,0 M - -
P/E ratio 2021 51,7x
Yield 2021 -
Capitalization 1 973 M 1 973 M -
EV / Sales 2021 6,42x
EV / Sales 2022 3,85x
Nbr of Employees 150
Free-Float -
Chart HARMONY BIOSCIENCES HOLDINGS, INC.
Duration : Period :
Harmony Biosciences Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HARMONY BIOSCIENCES HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 33,74 $
Average target price 57,00 $
Spread / Average Target 68,9%
EPS Revisions
Managers and Directors
John C.s Jacobs President, Chief Executive Officer & Director
Sandipkumar S. Kapadia Chief Financial Officer
Jeffrey S. Aronin Non-Executive Chairman
Jeffrey M. Dayno Chief Medical Officer
David Bradshaw Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
HARMONY BIOSCIENCES HOLDINGS, INC.-20.87%1 973
JOHNSON & JOHNSON-3.62%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-12.00%220 356